302 related articles for article (PubMed ID: 24481298)
1. Regulatory watch: Where do new medicines originate from in the EU?
Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
[No Abstract] [Full Text] [Related]
2. EU marketing authorization review of orphan and non-orphan drugs does not differ.
Putzeist M; Mantel-Teeuwisse AK; Llinares J; Gispen-De Wied CC; Hoes AW; Leufkens HG
Drug Discov Today; 2013 Oct; 18(19-20):1001-6. PubMed ID: 23835230
[TBL] [Abstract][Full Text] [Related]
3. More drugs originate outside the industry than it claims.
Young J
BMJ; 2014 Feb; 348():g1354. PubMed ID: 24496063
[No Abstract] [Full Text] [Related]
4. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
5. A future for regulatory science in the European Union: the European Medicines Agency's strategy.
Hines PA; Janssens R; Gonzalez-Quevedo R; Lambert AIOM; Humphreys AJ
Nat Rev Drug Discov; 2020 May; 19(5):293-294. PubMed ID: 32235873
[No Abstract] [Full Text] [Related]
6. Congress, the FDA, and the fair development of new medications for children.
McKinney RE
Pediatrics; 2003 Sep; 112(3 Pt 1):669-70. PubMed ID: 12949299
[No Abstract] [Full Text] [Related]
7. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
8. [EU law on marketing authorization of medicines. History, current state of development and perspectives].
Nettesheim M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781
[TBL] [Abstract][Full Text] [Related]
9. EMEA approves OGS drug rejected by FDA.
Mitchell P
Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
[No Abstract] [Full Text] [Related]
10. Data and market exclusivity for pharmaceuticals in the European Community.
Kingham RF; Castle GH
Food Drug Law J; 2000; 55(2):209-23. PubMed ID: 12269365
[No Abstract] [Full Text] [Related]
11. Orphan drug development across Europe: bottlenecks and opportunities.
Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
Drug Discov Today; 2008 Aug; 13(15-16):670-6. PubMed ID: 18583178
[TBL] [Abstract][Full Text] [Related]
12. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
13. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
Roman A
Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
[No Abstract] [Full Text] [Related]
14. "Bonne Année", "Gutes Neues Jahr"? Will 2007 be a "Happy New Year" for children's medicines in Europe?
Stephenson T
Arch Dis Child; 2007 Aug; 92(8):661-3. PubMed ID: 17642477
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceuticals. Adopt an orphan.
Karr A
Health Serv J; 1999 Nov; 109(5681):28. PubMed ID: 10724720
[No Abstract] [Full Text] [Related]
16. 1992 Le Tourneau Award. Problems with pharmaceutical regulation in the United States. Drug lag and orphan drugs.
Henry V
J Leg Med; 1993 Dec; 14(4):617-39. PubMed ID: 8308452
[No Abstract] [Full Text] [Related]
17. The Orphan Drug Act: an engine of innovation? At what cost?
Rohde DD
Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720
[No Abstract] [Full Text] [Related]
18. [The regulatory framework for complementary and alternative medicines in Europe].
Knöss W; Stolte F; Reh K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
[TBL] [Abstract][Full Text] [Related]
19. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
20. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
Doua JY; Van Geertruyden JP
Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
